Diseases [C] » Infections [C01] » Virus Diseases
Description
A general term for diseases caused by viruses. MeSH
Hierarchy View
Subtype Terms (16)
Arbovirus Infections
1 experimental drug
Bronchiolitis, Viral
6 drugs (5 approved, 1 experimental)
Central Nervous System Viral Diseases
1 experimental drug
DNA Virus Infections
6 drugs (5 approved, 1 experimental)
Hepatitis, Viral, Human
10 drugs (5 approved, 5 experimental)
Pneumonia, Viral
73 drugs (45 approved, 28 experimental)
RNA Virus Infections
28 drugs (11 approved, 17 experimental)
Sexually Transmitted Diseases, Viral
14 drugs (7 approved, 7 experimental)
Skin Diseases, Viral
1 approved drug
Tumor Virus Infections
7 drugs (6 approved, 1 experimental)
Viremia
10 drugs (8 approved, 2 experimental)
Phase 4 Indicated Drugs (21)
Phase 3 Indicated Drugs (24)
DTaP, inactivated poliovirus, haemophilus influenzae b conjugate, hepatitis b vaccine (Pediarix)
hepatitis b vaccine (recombinant) (Recombivax)
hexavalent pneumococcal polysaccharide vaccine
hydroxychloroquine (plaquenil)
Meningococcal (Groups A, C, Y, W) Conjugate Vaccine (MenQuadfi)
Phase 1 Indicated Drugs (17)
Other Experimental Indicated Drugs (8)
Organization Involved with Phase 4 Indications (60)
Canadian Institutes of Health Research (CIHR)
Centers for Disease Control and Prevention (CDC)
Centre Hospitalier Universitaire de la Réunion
Gottfried Wilhelm Leibniz Universität Hannover
Henan Provincal People's Hospital
Lower Saxony Center for Nephrology
Marshfield Clinic Research Foundation
Medical University of South Carolina
Methodist Cancer Center, Houston, Texas
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
University of British Columbia
University of California, Davis
University of California, San Francisco
Organization Involved with Phase 3 Indications (122)
Albert Einstein Israelite Hospital
Assistance Publique - Hôpitaux de Paris
Associazione Italiana per la Ricerca sul Cancro
Bill and Melinda Gates Foundation
Blekinge County Council Hospital
Cardresearch - Cardiologia Assistencial e de Pesquisa LTDA
Centro de Investigaciones Medicas y Ensayos Clinicos Dr Italo Fabbri
China National Biotec Group Co., Ltd
Chinese Academy of Medical Sciences
French National Agency for Research on AIDS and Viral Hepatitis
Government of the Democratic Republic of the Congo
Hoosier Cancer Research Network
Icahn School of Medicine at Mount Sinai
Indian Council of Medical Research
Inner Mongolia Autonomous Region Center for Diseases Prevention and Control (IMCDC)
Institut National de la Santé Et de la Recherche Médicale, France
International Center for Diarrheal Disease Research
Laboratorio Elea S.A.C.I.F. y A.
National Cancer Institute (NCI)
National Institute for Research in Tuberculosis, Chennai, India
National Institutes of Health (NIH)
Queensland Children's Hospital
Research Institute of Influenza, Russia
RojanPharma Pharmaceutical Company
Second Military Medical University
Shanghai Zerun Biotechnology Co.,Ltd
Organization Involved with Phase 2 Indications (187)
ABF Pharmaceutical Services GmbH
AmpliPhi Biosciences Corporation
Aristotle University of Thessaloniki
Australian Respiratory and Sleep Medicine Institute
Beijing Institute of Biotechnology
Beijing Institute of Pharmacology and Toxicology
Blood and Marrow Transplant Clinical Trials Network
Centers for Disease Control and Prevention, China
Centre de Recherche St-Louis, Quebec, Canada
Centre Hospitalier Universitaire de Pointe-a-Pitre
Children's National Medical Center
Chinese University of Hong Kong
Chronic Obstructive Pulmonary Disease Trial Network, Denmark
Eastern Cooperative Oncology Group
ECOG-ACRIN Cancer Research Group
Envigo Pharma Consulting Limited
Epicentre, Paris, France and Mbarara, Uganda
Government of the Republic of Guinea
Hannover Clinical Trial Center GmbH
Hualan Biological Bacterin Co. Ltd.
Huazhong University of Science and Technology
Indiana Clinical Trials Center
International AIDS Vaccine Initiative
Medical Research Council-UVRI Uganda Research Unit on AIDS
Medical University of Southern Africa
Ministry of Health & Sanitation
National Heart, Lung, and Blood Institute (NHLBI)
National Institute for Health Research, United Kingdom
Norwich Clinical Research Associates Ltd.
Omnispec Clinical Research Inc, Mirabel, Canada
Orlando Clinical Research Center
People's Liberation Army of China
Perinatal HIV Research Unit, Baragwanath
Puerto Rico Clinical and Translational Reserach Consortium
Russian Academy of Medical Sciences
Sanotize Research and Development Corp.
Shenzhen Third People's Hospital
Shin Nippon Biomedical Laboratories
Sierra Leone-China Friendship Hospital
Tianjin Cansino Biotechnology Inc
Topstone Research, Toronto, Canada
Tropical Diseases Hospital, Ho Chi Minh City
University Hospital Pointe-a-Pitre, Guadeloupe
University of North Carolina at Chapel Hill
University of Texas at Houston
University of the French West Indies and French Guiana
Vita-Salute University of Milano. Italy
Washington University in St. Louis
Zambia-Emory HIV Research Project
Organization Involved with Phase 1 Indications (86)
Canadian Science Centre for Human and Animal Health
Centre Hospitalier Universitaire le Dantec
Clinical Research Services Turku
Health Sciences Centre Foundation, Manitoba
Ichor Medical Systems Incorporated
ImmunoVaccine Technologies, Inc.
Massachusetts Institute of Technology
National Microbiology Laboratory, Canada
National University of Singapore
Oklahoma Medical Research Foundation
Pharmaceutical Research Associates, Inc. (PRA)
Philipps University of Marburg
Organization Involved with Other Experimental Indications (23)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
